Last time I checked, we had freedom of speech. Yes, even on the internet. It's morons like you that may not be aware of that. We are ALLOWED to exchange information!!! Amazing, isn't it???
Anyone can find a "BUY" or "SELL" rating on any stock at any time. There are few biotechnology companies worth buying
because most of them are frauds. A drug will receive a high rating and then fade into oblivion a few months or years later as people
discover it doesn't work as claimed. Thalidomide is just ONE example of this fraud. Chirally pure Ritalin is another example, as it
is no more effective than plain Ritalin. (Ritalin, by the way, was discovered by accident by another company, thirty years ago.
It's nothing but a slightly modified amphetamine molecule).
So much for multi-million dollar research, right? Research that is paid for by stockholders and taxpayers. So, where does most of this money go?
dookiebite has probably lost his ass in margins
and cover calls, not because of anything but
stupidity. There is more information about celegene out
there than one person can shake a stick at. Dookie bite
you are the problem. Grow up.
just responded to a message that is over TWO
YEARS old?!? In internet time, that is like 500 years
ago. This "dookiebite" character you responded to has
not been seen or heard of on this message board in
over two years either.
i spoke with investor relations.....they told me that although one can never be cetain what the fda will do and when, they believe the analysts(Prudential, and others) are right and they would be surprised if approval was not here by the end of the first quarter. good luck to all!!!!!
Composition of matter patents mean that the compound has patent protection on the compound itself, not just the uses. CELG has patents on certain uses of thalidomide, it doesn't have a composition of matter patent on the product itself.
patience is a virtue.... can you wait 3 more weeks for a 20% gain in this stock? I can and will; we are on the verge of the long awaited move, do not lose heart now. we will avail over enmd for sure
composition of matter patent protection is not availiable for thalidomide, but enmd was granted rights to thalidomide for
antiangiogenesis uses. there are at least 2 other issued patents covering certain nonanantiangiogenic uses of thalidomide. bmy was orginally
the licensed co. for thalidomide, but rights to the drug have subsequently been returned to enmd. bmy continues to hold rights
to thalidomide analogs for which enmd will receive product royalties ranging from 8%-12.5% depending on sales volume.